Sanofi prunes its pipeline, taking the ax to a lineup of drug, vaccine programs
Sanofi swept away a lineup of drug and vaccine programs in its Q2 update, starting with a late-stage vaccine play with Daiichi Sankyo and running right through setbacks on their CD38 drug, the anti-inflammatory Kevzara, as well as a troubled alliance with Denali on ALS.
Gone is a longstanding Phase III development program with Daiichi Sankyo for a pediatric pentavalent vaccine in Japan, though there’s no word on what prompted the pullback.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.